alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 74, Number 100 (Wednesday, May 27, 2009)]
[Notices]
[Page 25247]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-12198]



[[Page 25247]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Eunice Kennedy Shriver National Institute of Child Health & Human 
Development; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel; Mexican Children of Immigrants 
Program.
    Date: June 15, 2009.
    Time: 1 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6100 Executive Boulevard, 
Room 5B01, Rockville, MD 20852, (Telephone Conference Call)
    Contact Person: Carla T. Walls, PhD, Scientific Review 
Administrator, Division of Scientific Review, National Institute of 
Child Health and Human Development, NIH, 6100 Executive Blvd., Room 
5B01, Bethesda, MD 20892, (301) 435-6898, <a href="/cdn-cgi/l/email-protection#8bfceae7e7f8e8cbe6eae2e7a5e5e2e3a5ece4fd"><span class="__cf_email__" data-cfemail="d5a2b4b9b9a6b695b8b4bcb9fbbbbcbdfbb2baa3">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: May 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-12198 Filed 5-26-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<TABLE> <S> <C>



<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                       1,514,561
<SECURITIES>                                   158,000
<RECEIVABLES>                                  664,172
<ALLOWANCES>                                    30,000
<INVENTORY>                                  1,616,990
<CURRENT-ASSETS>                             4,135,868
<PP&E>                                       1,107,464
<DEPRECIATION>                                 638,161
<TOTAL-ASSETS>                               4,784,511
<CURRENT-LIABILITIES>                          795,935
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        44,574
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 4,784,511
<SALES>                                      6,162,986
<TOTAL-REVENUES>                             6,162,986
<CGS>                                        3,624,603
<TOTAL-COSTS>                                2,849,068
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               4,417
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (196,098)
<EPS-PRIMARY>                                     (.05)
<EPS-DILUTED>                                     (.05)
        



</TABLE>
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.12    
    


July 21,
2006 


Duke
Energy Murray Operating, LLC

139 East Fourth Street

5 Atrium II

Cincinnati, Ohio 45202 


Attn:
Mr. Dave Ledonne, Contract Manager 


        Reference
is made to the Operation and Maintenance Agreement dated August 5, 2004 ("Agreement") between Duke Energy Murray Operating, LLC ("DEMO") and KGen Murray I and II LLC
("KGen Murray"). 


        DEMO
and KGen Murray, hereby agree that subject to the Lenders Consents described below, Section 6.5 of the Agreement is amended by replacing the reference to "sixty
(60) days" contained therein to "one hundred twenty (120) days." 


        The
amendment described above shall be effective upon the date that KGen Murray notifies DEMO that KGen Murray has received all consents and approvals of its lenders necessary for the
amendment of the Agreement contained herein ("Lenders Consents"). KGen Murray agrees that it shall provide DEMO prompt notice of its receipt of the Lender Consents. 


        Except
as amended hereby, the Agreement shall remain in full force and effect. 


[Signatures
follow] 







 


	 	 	 	 	KGEN MURRAY I AND II LLC
	

 	
 	

 	
 	

By:	
 	

/s/ Donald E. Boyd
 Donald E. Boyd

Sr. Vice President—Operations
	

AGREED TO AND ACKNOWLEDGED BY:	
 	

 	
 	

 
	

DUKE ENERGY MURRAY OPERATING LLC	
 	

 	
 	

 
	

By:	
 	

/s/ David A. Ledonne
	
 	

 	
 	

 
	

Name:	
 	

David A. Ledonne
	
 	

 	
 	

 
	

Title:	
 	

Contract Manager
	
 	

 	
 	

 




2











QuickLinks



Exhibit 10.12
**Exhibit 31.1**

**CERTIFICATION**

I, John B. Wood, certify that: 

1. I have reviewed this quarterly report onForm 10-Q of Telos Corporation; 

2. Based on my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in allmaterial respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to bedesigned under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presentedin this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internalcontrol over financial reporting; and 

5. The registrant’s other certifying officer and I have disclosed, based onour most recent evaluation of internal control over financial reporting, to the registrant’s auditors and to the audit committee of registrant’s board of directors: 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financialreporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
The Honorable Gary A. Fenner, United States District Judge for the Western

1

District of Missouri.

United States Court of Appeals

FOR THE EIGHTH CIRCUIT

___________

No. 97-3324

___________

Janice Rukavina, *

 *

Appellant, *

 *

v. * Appeal from the United States

 * District Court for the

Missouri Department of Social * Western District of Missouri. 

Services, Division of Child Support *

Enforcement; Kathleen Shannon, * [UNPUBLISHED]

Supervisor 1; David Damico, *

Program Director, *

 *

Appellees. *

___________

 Submitted: February 5, 1999

 Filed: February 16, 1999

___________

Before FAGG, HANSEN, and MORRIS SHEPPARD ARNOLD, Circuit Judges. 

___________

PER CURIAM.

Janice Rukavina appeals from the district court’s grant of summary judgment 1

in favor of her former employer and the manager of her office. Having reviewed the
-2-

record de novo and the parties’ briefs, we affirm the judgment with regard to Ms.

Rukavina’s disability discrimination claim because she failed to offer sufficient

evidence to create a factual dispute whether she was a “qualified” individual--i.e.,

whether she could perform the essential duties of her position with or without

reasonable accommodation. See Hennenfent v. Mid Dakota Clinic, P.C., No. 98-1992,

1998 WL 901709 (8th Cir. Dec. 29, 1998). As to Ms. Rukavina’s other claims, we

affirm for the reasons stated by the district court. See 8th Cir. R. 47B.

A true copy.

Attest:

 CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-1997
<PERIOD-START>                             JUL-01-1996
<PERIOD-END>                               JUN-30-1997
<CASH>                                           6,290
<SECURITIES>                                     9,542
<RECEIVABLES>                                   18,288
<ALLOWANCES>                                     6,263
<INVENTORY>                                        481
<CURRENT-ASSETS>                                29,805
<PP&E>                                          24,406
<DEPRECIATION>                                  15,898
<TOTAL-ASSETS>                                  41,778
<CURRENT-LIABILITIES>                           27,053
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                     30,292
<COMMON>                                            20
<OTHER-SE>                                    (15,864)
<TOTAL-LIABILITY-AND-EQUITY>                    41,778
<SALES>                                         30,320
<TOTAL-REVENUES>                                58,104
<CGS>                                            5,131
<TOTAL-COSTS>                                   16,258
<OTHER-EXPENSES>                                41,596
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (4,881)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (4,881)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (4,881)
<EPS-PRIMARY>                                   (0.25)
<EPS-DILUTED>                                   (0.25)
        

</TABLE>
July 1, 2023              BASIC            

Maria I. Morasso, Ph.D. 

|

Laboratory of Skin Biology

|

## Description

The outermost layer of the skin—the epidermis—is broadly divided into the proliferating basal fraction and the differentiated suprabasal fraction. Skin cells within the epidermis maintain a balance between division and differentiation through distinct morphologic stratification and temporospatial gene expression. The authors of this study used a multifaceted approach to generate datasets that may provide details of the complex epigenomic landscape of epidermal differentiation. They also revealed unique roles for Dlx3, a crucial regulator of hair follicle differentiation and cycling, and the proteins it targets in the regulation of skin development.

## What is exciting about this article?

This study generated a comprehensive topographic, transcriptomic, and epigenomic analysis of the skin epidermis through a profile of proliferating basal cells and differentiated suprabasal cells from murine epidermis. The findings represent an epigenomic map of epidermal differentiation during skin development, an invaluable resource for future studies.

## How does this fit into the larger NIAMS portfolio?

Results from this study aid in the understanding of cellular differentiation in the skin epidermis at the genomic, epigenomic, and transcriptional levels. It may also offer an opportunity to further understand chromatin dysregulation in the context of skin diseases.

## Grant support

AR041171

Research Areas:
Cancer BiologyDevelopmental BiologyGenetics and GenomicsMolecular Biology and BiochemistrySkin Biology

CORE Facilities:

Biodata Mining and Discovery Section

Genomic Technology Section

Reference:

###             Chromatin Landscape Governing Murine Epidermal Differentiation.        

143(7).

Research reported in this publication was supported by the Intramural Research Program of the NIHʼs National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Previous

See All Advances

Next

## Recent Advances

Selected recent highlights of NIAMS intramural research:

October 3, 2023

The Transcription Factor STAT4 Controls the Fate of Cytotoxic Innate Lymphocytes

September 26, 2023

The Microbiomes of People with Recombination-Activating Gene (RAG) Deficiency Have Distinct Features, Including Antimicrobial Resistance Signatures 

September 26, 2023

Genetic Variants of PLCG2 Cause Immune Dysregulation Through Either Increased or Decreased Function

September 23, 2023

Neutrophil Extracellular Traps (NETs) Trigger Pathogenic Inflammation and Bone Loss in Periodontitis

September 22, 2023

Possible Mechanism of a Rare Bone Overgrowth Disease Identified

Back to Top
**EXHIBIT 32.02**

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, the Chief Financial Officer of Martek Biosciences Corporation (“the Company”), hereby certifies that, to his knowledge, on the date hereof:

 

a)              Amendment No. 1 to the annual report on Form 10-K of the Company for the period ended October 31, 2010 filed on the date hereof with the Securities and Exchange Commission (“the Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

b)             Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
| Date: February 25, 2011 |                |
|------------------------------|---------------------|
|                         |                |
|                         |                |
| By                           | /s/   Peter L. Buzy |   |
| Peter L. Buzy                |                |
| Chief Financial Officer      |                |
|                         |                |
|                              |                     |  |

 

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Martek Biosciences Corporation and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

----
{"version":"1.0","provider_name":"National Intelligence University","provider_url":"https:\/\/www.ni-u.edu","author_name":"ray.x.villarreal@odni.gov","author_url":"https:\/\/www.ni-u.edu\/author\/ray-x-villarrealodni-gov\/","title":"Graduation Information","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"0An4CjUd27\"><a href=\"https:\/\/www.ni-u.edu\/graduation-2\/\">Graduation Information<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.ni-u.edu\/graduation-2\/embed\/#?secret=0An4CjUd27\" width=\"600\" height=\"338\" title=\"“Graduation Information” — National Intelligence University\" data-secret=\"0An4CjUd27\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n"}
<PAGE>


                              A-FEM MEDICAL CORPORATION             Exhibit 11.1
                         CALCULATIONS OF NET INCOME PER SHARE

<TABLE>
<CAPTION>


                                                For the three months ended    For the six months ended
                                                          June 30                       June 30
                                               ----------------------------  -----------------------------
                                                    1997           1996           1997            1996
                                               -------------  -------------  -------------   -------------
<S>                                            <C>            <C>            <C>             <C>
Actual weighted average shares outstanding       12,473,982      8,956,484     12,133,708      8,952,363
for the period

Dilutive common stock, options and warrants       1,317,444         - (1)       1,315,585          -(1)
using the treasury stock method
                                               -------------  -------------  -------------   -------------
Total shares used in per share calculations      12,473,982      8,956,484     12,133,708      8,952,363
                                               -------------  -------------  -------------   -------------
Net income (loss)                                $1,046,432    ($1,069,593)      $411,033    ($2,082,644)
                                               -------------  -------------  -------------   -------------

Net income (loss) per share                           $0.08         ($0.12)         $0.03         ($0.23)
                                               -------------  -------------  -------------   -------------
                                               -------------  -------------  -------------   -------------

</TABLE>

(1) Warrants and options outstanding are not included as the effect would be 
anti-dilutive.


                                                                       PAGE 13
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. 998 Introduced in Senate (IS)]

  1st Session
                                 S. 998

 To include the State of Idaho as an affected area under the Radiation 
            Exposure Compensation Act (42 U.S.C. 2210 note).

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 11, 2005

 Mr. Crapo (for himself and Mr. Craig) introduced the following bill; 
  which was read twice and referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
 To include the State of Idaho as an affected area under the Radiation 
            Exposure Compensation Act (42 U.S.C. 2210 note).

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. INCLUSION OF IDAHO IN RADIATION EXPOSURE COMPENSATION.

    Section 4(b)(1) of the Radiation Exposure Compensation Act (42 
U.S.C. 2210 note) is amended--
            (1) in subparagraph (B), by striking ``and'' after the 
        semicolon; and
            (2) by adding after subparagraph (C) the following:
                    ``(D) the State of Idaho; and''.
                                 <all>
```